Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
about
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingA first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsMouse models of pancreatic cancerTherapeutic targeting of replicative immortalityLong-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancerRas oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread-Identification of a Promising Novel therapeutic target.A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.Screening for genes and subnetworks associated with pancreatic cancer based on the gene expression profileNotch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis.Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sitesClinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination SystemInhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancerCell cycle proteins as promising targets in cancer therapyEmerging cell-cycle inhibitors for pancreatic cancer therapy.Cyclin-dependent kinase inhibitors closer to market launch?Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.Dinaciclib for the treatment of breast cancer.A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP InhibitionMYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.CK1δ activity is modulated by CDK2/E- and CDK5/p35-mediated phosphorylation.Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner.The Emerging Role of Cdk5 in CancerThe gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma.Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis.Synthesis and Anti-Proliferative Effects of Mono- and Bis-Purinomimetics Targeting Kinases.
P2860
Q21133611-430FF802-2F4E-4296-99E8-5578674FDBB9Q21245492-DFAECC61-D276-43E0-858E-91380AFEC8D8Q26827580-293D3315-8A16-4EC2-9DA6-B83CBFE0F026Q26860574-3FC50205-B03F-44EE-84C5-FB57D0303941Q27027457-C3E4EBB4-1944-4340-A5B3-CF2178C0D1D8Q27853310-7E3FFE74-0A5A-4F69-943A-4E54F75A1AD0Q28076548-803625F7-6134-4E72-A13A-5CD9046540ACQ33702030-1C6BA09F-E6B4-4F76-9F0B-DB96C3605A28Q33779805-BCDFE959-0D4C-4690-93BE-4B14A4ED50CDQ34195072-767F3ABD-5BA6-485A-8727-848616C305F1Q34301314-81C35780-FDDD-42DC-9506-8635B3B87B0AQ36020882-C5D23595-15ED-47AB-88C8-35D3BCB81058Q36037996-477CB7B8-0B22-4CF4-9C50-67493464454CQ36282782-CE8DDE7F-30B0-4FF8-9D76-78FED66790AEQ36817494-04DECEB4-DD71-49F7-A1F8-111251809928Q36881446-552D4BD7-5632-42CA-AE1C-A7F022EF06F0Q36905854-F302EB39-8ACD-4E2B-A8A7-94A7392293F8Q37086209-1C296103-ECD1-4C32-BD89-0D429B1548E8Q37199802-4E6EC54D-04E4-4095-AFCC-AEEFF2FFF6AAQ37611396-2B81019E-BD5F-4C22-A625-762071E5E182Q37611723-2AF0D868-C347-4BD3-AFFD-3500560751B4Q37636710-54E3B1E5-9EA5-497B-8E96-B71FFD265C82Q37693690-9A7E7C54-941B-4AD5-A7BD-471AA35D8B27Q38057759-6A2C3CC4-AF6B-4DB7-B0C6-A5841927D6E2Q38100203-C5CD2521-7D7D-43ED-BFCD-57AB8CDB45F7Q38175443-668098FD-525D-4B02-9F30-6DA63E6050EDQ38238282-76560851-0291-460B-99D7-7675C87845B0Q38324762-C246AE8D-43BE-4D30-91F8-439928F55116Q38539670-F7441154-71ED-49D9-A3AB-00DB1AF4FCB8Q38734002-8EBFB134-F34E-4988-A35B-1DF40055A6A0Q38758760-06D0FF2C-555D-4B65-A6AE-0BD99733D646Q38828117-E79DE652-145B-4C1F-99C7-A718E5E1215BQ38865573-878188FC-5DD7-45E1-8554-2304921FCE5EQ39029140-A46FF020-8300-42D7-BC1D-7D6FE0D33616Q39321505-89A6AD30-E5D0-47FD-848B-A3505691567BQ40041197-642CE690-3479-4537-B469-85EAE752623EQ40989800-174D129D-3C4B-488D-BED9-284E81C7A33EQ41867443-6DA1F57A-D3DA-4010-9DBF-E694CDBAC5F3Q42130838-AEC67AC2-1A87-4AEC-A02F-CC3750AE814BQ47161171-3D77D00D-63DD-40DD-8729-24B21C863884
P2860
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cyclin-dependent kinase inhibi ...... ion in murine xenograft models
@ast
Cyclin-dependent kinase inhibi ...... ion in murine xenograft models
@en
Cyclin-dependent kinase inhibitor Dinaciclib
@nl
type
label
Cyclin-dependent kinase inhibi ...... ion in murine xenograft models
@ast
Cyclin-dependent kinase inhibi ...... ion in murine xenograft models
@en
Cyclin-dependent kinase inhibitor Dinaciclib
@nl
prefLabel
Cyclin-dependent kinase inhibi ...... ion in murine xenograft models
@ast
Cyclin-dependent kinase inhibi ...... ion in murine xenograft models
@en
Cyclin-dependent kinase inhibitor Dinaciclib
@nl
P2093
P2860
P356
P1476
Cyclin-dependent kinase inhibi ...... ion in murine xenograft models
@en
P2093
Anirban Maitra
Anjali Mishra
Barry D Nelkin
Collins Karikari
Georg Feldmann
Hector Alvarez
Manuel Hidalgo
N V Rajeshkumar
Niki A Ottenhof
Peter Brossart
P2860
P304
P356
10.4161/CBT.12.7.16475
P577
2011-10-01T00:00:00Z